MCM
KRYS icon

MAI Capital Management’s Krystal Biotech KRYS Stock Holding History

MAI Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$385K Buy
1,035
+25
+2% +$7.47K ﹤0.01% 1447
2026
Q1 		$261K Buy
1,010
+726
+256% +$193K ﹤0.01% 1340
2025
Q4 		$70K Hold
284
– – ﹤0.01% 1825
2025
Q3 		$50.1K Buy
284
+126
+80% +$18.9K ﹤0.01% 1924
2025
Q2 		$21.7K Buy
158
+24
+18% +$3.52K ﹤0.01% 2315
2025
Q1 		$24.2K Hold
134
– – ﹤0.01% 2103
2024
Q4 		$21K Buy
+134
New +$23.8K ﹤0.01% 2198

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

MAI Capital Management's KRYS Position: Q2 2026 in Review

MAI Capital Management increased its Krystal Biotech (KRYS) stake by 2.5% in Q2 2026, buying an estimated $7.47K and bringing the position to 1,035 shares worth $385K. The position accounts for ﹤0.01% of the portfolio, ranked #1447.

MAI Capital Management first reported a position in KRYS in Q4 2024 and has held it in 7 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • MAI Capital Management held 1,035 shares of Krystal Biotech worth $385K as of Q2 2026.
  • MAI Capital Management bought 25 Krystal Biotech shares in Q2 2026, an estimated $7.47K.
  • Krystal Biotech made up ﹤0.01% of MAI Capital Management's portfolio in Q2 2026, its #1447 holding.
  • MAI Capital Management first reported a position in Krystal Biotech in Q4 2024 and has held it in 7 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.